Abstract
Primary aldosteronism is a frequent form of endocrine hypertension comprising both sporadic and familial forms. Three forms of familial hyperaldosteronism have been described to date. In this chapter we discuss the clinical phenotypes and the genetic basis of familial hyperaldosteronism type III. This condition is caused by a mutation in the KCNJ5 gene, encoding the potassium channel GIRK4 (also called Kir 3.4), that alters the selectivity filter of the ion channel. In the presence of these mutations, aldosterone secretion is increased leading to a particularly severe form of hyperaldosteronism with early-onset hypertension that is usually resistant to pharmacological treatment and requires bilateral adrenalectomy.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ACTH:
-
Adrenocorticotropic hormone
- ADX:
-
Adrenalectomy
- APA:
-
Aldosterone-producing adenoma
- CYP11B1:
-
11β-Hydroxylase
- CYP11B2:
-
Aldosterone synthase
- DBP:
-
Diastolic blood pressure
- FH-III:
-
Familial hyperaldosteronism type III
- PA:
-
Primary aldosteronism
- PRA:
-
Plasma renin activity
- SBP:
-
Systolic blood pressure
References
Conn JW (1955) Primary aldosteronism. J Lab Clin Med 45:661–664
Ganguly A (1998) Primary aldosteronism. N Engl J Med 339:1828–1834
Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89:1045–1050
Mulatero P, Milan A, Williams TA, Veglio F (2006) Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovasc Hematol Agents Med Chem 4:75–91
Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243–1248
Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM (1992) A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262–265
Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F, Stowasser M (2008) Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens 26:1577–1582
Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP (2008) A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 93:3117–3123
Mulatero P (2008) A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III. J Clin Endocrinol Metab 93:2972–2974
Therien B, Mellinger RC, Caldwell JR, Howard PJ (1959) Primary aldosteronism due to adrenal hyperplasia; occurrence in a boy aged 10 years. AMA J Dis Child 98:90–99
Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG (1992) Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 116:813–820
Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP (2011) K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331:768–772
Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA (2013) Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol 9(2):104–112. doi:10.1038/nrendo.2012.230
Wickman K, Nemec J, Gendler SJ, Clapham DE (1998) Abnormal heart rate regulation in GIRK4 knockout mice. Neuron 20:103–114
Kovoor P, Wickman K, Maguire CT, Pu W, Gehrmann J, Berul CI, Clapham DE (2001) Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol 37:2136–2143
Yang Y, Yang Y, Liang B, Liu J, Li J, Grunnet M, Olesen SP, Rasmussen HB, Ellinor PT, Gao L, Lin X, Li L, Wang L, Xiao J, Liu Y, Liu Y, Zhang S, Liang D, Peng L, Jespersen T, Chen YH (2010) Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 86:872–880
Monticone S, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV, Pezzani R, Auchus RJ, Ghayee HK, Shibata H, Kurihara I, Williams TA, Giri JG, Bollag RJ, Edwards MA, Isales CM, Rainey WE (2012) Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 97:E1567–E1572
Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ (2012) Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 97:E819–E829
Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E, Tizzani D, Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S, Penton D, Plouin PF, Warth R, Allolio B, Jeunemaitre X, Veglio F, Reincke M (2012) KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 59:235–240
Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP (2012) Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 109:2533–2538
Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP (2012) A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 97:E1532–E1539
Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE (2012) Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 153:1774–1782
Mulatero P, Williams TA, Monticone S, Veglio F (2011) Is familial hyperaldosteronism underdiagnosed in hypertensive children? Hypertension 57:1053–1055
Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D, Williams TA, Einaudi S, La Grotta A, Rabbia F, Veglio F (2011) Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 58:797–803
Mussa A, Camilla R, Monticone S, Porta F, Tessaris D, Verna F, Mulatero P, Einaudi S (2012) Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism. Endocr J 59:497–502
Bartter FC, Biglieri EG (1958) Primary aldosteronism: clinical staff conference at the National Institutes of Health. Ann Intern Med 48:647–654
Greco RG, Carroll JE, Morris DJ, Grekin RJ, Melby JC (1982) Familial hyperaldosteronism, not suppressed by dexamethasone. J Clin Endocrinol Metab 55:1013–1016
Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G, Rabbia F, Terzolo M, Gomez-Sanchez EP, Gomez-Sanchez CE, Veglio F (2012) 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab 97:881–889
Amlal H, Krane CM, Chen Q, Soleimani M (2000) Early polyuria and urinary concentrating defect in potassium deprivation. Am J Physiol Renal Physiol 279:F655–F663
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Williams, T.A., Monticone, S., Veglio, F., Mulatero, P. (2014). Familial Hyperaldosteronism Type III. In: Hellman, P. (eds) Primary Aldosteronism. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0509-6_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0509-6_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0508-9
Online ISBN: 978-1-4939-0509-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)